Document is current
Any future updates will be listed below
-
Authors
Llibre-Guerra, Jorge J. https://orcid.org/0000-0002-2137-7750
McDade, Eric M. https://orcid.org/0000-0002-6764-3866
Schindler, Suzanne E. https://orcid.org/0000-0002-1680-1465
Clifford, David B.
Supnet, Charlene
Atri, Alireza
Bateman, Randall J. https://orcid.org/0000-0002-7729-1702
- License Information
-
More Information
Article History
Accepted: 18 September 2025
First Online: 3 November 2025
Competing interests
: J.J.L.-G.’s research is supported by the National Institutes of Health National Institute of Aging (K01AG073526), the Alzheimer’s Association (AARFD-21-851415, SG-20-690363, 24HPE-1287320), the Michael J. Fox Foundation (MJFF-020770) and The Foundation for Barnes–Jewish Hospital. E.M.McD. has received research funding from the Alzheimer’s Association, Eisai, Eli Lilly, GHR, Hoffman–La Roche, and the National Institutes of Health. E.M.McD. has served as a consultant or adviser for Alzamend, AstraZeneca, Hoffman–La Roche, Ionis and Sanofi. E.M.McD. has served as a data and safety monitoring board member for Alector and Alnylum, and is on the scientific advisory board for Foundation Alzheimer. S.E.S. has served on scientific advisory boards related to biomarker testing and education for companies including Eisai, Eli Lilly and Novo Nordisk. D.B.C. receives royalties from Wolters Kluwer. D.B.C. serves as scientific consultant to Atara Biotherapeutics, Cellevolve Bio, Excision BioTherapeutics, F. Hoffmann–La Roche/Genentech, ICON (Teva), Sanofi Genzyme, Seagen and Wave Life Sciences. D.B.C. has carried out legal consulting for Lewis, Thomason, King, Krieg and Waldrop and Loughren, Loughren, Loughren Powell Gilbert. D.B.C. serves on the data safety monitoring boards for Atara Biotherapeutics, Avidity, Cellevolve Bio, Excision Biotherapeutics, Morphic, Sanofi Genzyme, Teva and Wave Life Sciences. A.A. has received consulting fees from multiple pharmaceutical and biotechnology companies, including Eisai, Lundbeck, Merck, Novo Nordisk, Prothena and Roche/Genentech. A.A.’s institution receives grant and research support from the National Institutes of Health (NIH), the State of Arizona, Gates Ventures and several industry partners. R.J.B. receives laboratory research funding from the Alzheimer’s Association, Association for Frontotemporal Degeneration, Association for Frontotemporal Degeneration FTD Biomarkers Initiative, Avid Radiopharmaceuticals, BrightFocus Foundation, Centene Corporation, Coins for Alzheimer’s Research Trust Fund, the Cure Alzheimer’s Fund, DIAN-TU Pharma Consortium, Good Ventures Foundation, Janssen, the National Institutes of Health, the NfL Consortium (AbbVie, Biogen, Bristol Meyers Squibb, Hoffman La Roche), Novartis, Rainwater Foundation, Tau Consortium, Tau SILK Consortium (AbbVie, Biogen, Eli Lilly and Company and an anonymous organization), The Foundation for Barnes–Jewish Hospital and the Tracy Family SILQ Center. Washington University and R.J.B. have equity ownership interest in C2N Diagnostics and receive income based on technology (stable isotope labelling kinetics, blood plasma assay, and methods of diagnosing AD with phosphorylation changes) licensed by Washington University to C2N Diagnostics. C.S. declares no financial competing interests.
